1. European Association for the Study of the Liver . EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182–236.
Google Scholar | Crossref | Medline2. Kang, YJ, Lee, BC, Kim, JK, et al. Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating Barcelona clinic liver cancer stage 0/A hepatocellular carcinoma. Cardiovasc Intervent Radiol 2020;43:55–64.
Google Scholar | Crossref | Medline3. Cho, J-Y, Paik, Y-H, Park, HC, et al. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver Int 2014;34:795–801.
Google Scholar | Crossref | Medline | ISI4. Yoon, SM, Ryoo, B-Y, Lee, SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol 2018;4:661–669.
Google Scholar | Crossref | Medline5. Paik, EK, Kim, M-S, Jang, WI, et al. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol 2016;11:22.
Google Scholar | Crossref | Medline6. Krishnan, S, Dawson, LA, Seong, J, et al. Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol 2008;15:1015–1024.
Google Scholar | Crossref | Medline | ISI7. Ursino, S, Greco, C, Cartei, F, et al. Radiotherapy and hepatocellular carcinoma: update and review of the literature. Eur Rev Med Pharmacol Sci 2012;16:1599–1604.
Google Scholar | Medline8. Jacob, R, Turley, F, Redden, DT, et al. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 Cm. HPB 2015;17:140–149.
Google Scholar | Crossref | Medline9. Sieghart, W, Hucke, F, Peck-Radosavljevic, M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 2015;62:1187–1195.
Google Scholar | Crossref | Medline10. Facciorusso, A, Mariani, L, Sposito, C, et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:645–653.
Google Scholar | Crossref | Medline | ISI11. Zeng, Z-C, Seong, J, Yoon, SM, et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific primary liver cancer expert meeting. Liver Cancer 2017;6:264–274.
Google Scholar | Crossref | Medline12. Kohla, MAS, Abu Zeid, MI, Al-Warraky, M, et al. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterol 2015; 2: e000032.
Google Scholar | Crossref | Medline13. Li, J-X, Wu, H, Huang, J-W, et al. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. J Formos Med Assoc 2012;111:510–515.
Google Scholar | Crossref | Medline14. Lencioni, R, Montal, R, Torres, F, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017;66:1166–1172.
Google Scholar | Crossref | Medline15. Tu, J, Jia, Z, Ying, X, et al. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma. Medicine 2016;95:e5606.
Google Scholar | Crossref | Medline16. Hsu, H-Y, Yu, M-C, Lee, C-W, et al. RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma. BMC Cancer 2017;17:742.
Google Scholar | Crossref | Medline17. Yamakado, K, Miyayama, S, Hirota, S, et al. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the child-pugh score: subclassifying the intermediate stage (Barcelona clinic liver cancer stage B). Jpn J Radiol 2014;32:644–649.
Google Scholar | Crossref | Medline18. Angelico, M . TACE vs DEB-TACE: who wins? Dig Liver Dis 2016;48:796–797.
Google Scholar | Crossref | Medline19. Golfieri, R, Giampalma, E, Giampalma, E, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014;111:255–264.
Google Scholar | Crossref | Medline20. Seki, A, Hori, S. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2012;35:555–562.
Google Scholar | Crossref | Medline | ISI21. Biggins, SW, Kim, WR, Terrault, NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652–1660.
Google Scholar | Crossref | Medline | ISI22. Johnson, PJ, Berhane, S, Kagebayashi, C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550–558.
Google Scholar | Crossref | Medline | ISI23. Dhanasekaran, R, Kooby, DA, Staley, CA, et al. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. HPB 2010;12:174–180.
Google Scholar | Crossref | Medline | ISI24. Piscaglia, F, Ogasawara, S. Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment. Liver Cancer 2018;7:104–119.
Google Scholar | Crossref | Medline25. Raoul, J-L, Sangro, B, Forner, A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212–220.
Google Scholar | Crossref | Medline | ISI26. Lencioni, R, de Baere, T, Soulen, MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016;64:106–116.
Google Scholar | Crossref | Medline | ISI27. Cammà, C, Schepis, F, Orlando, A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47–54.
Google Scholar | Crossref | Medline | ISI28. Sakamoto, I, Iwanaga, S, Nagaoki, K, et al. Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR Am J Roentgenol 2003;181:79–87.
Google Scholar | Crossref | Medline29. Arslan, M, Degirmencioglu, S. Liver abscesses after transcatheter arterial embolization. J Int Med Res 2019;47:1124–1130.
Google Scholar | SAGE Journals | ISI30. Dhamija, E, Paul, SB, Gamanagatti, SR, et al. Biliary complications of arterial chemoembolization of hepatocellular carcinoma. Diagn Interv Imaging 2015;96:1169–1175.
Google Scholar | Crossref | Medline31. Malagari, K, Pomoni, M, Spyridopoulos, TN, et al. Safety profile of sequential transcatheter chemoembolization with DC BeadTM: results of 237 Hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 2011;34:774–785.
Google Scholar | Crossref | Medline32. Macomber, MW, Schaub, SK, Apisarnthanarax, S. Case reports: liver abscess after hepatic stereotactic body radiation therapy. Pract Radiat Oncol 2018;8:e255–e258.
Google Scholar | Crossref | Medline33. Yu, JI, Park, HC, Lim, DH, et al. Do biliary complications after hypofractionated radiation therapy in hepatocellular carcinoma matter? Cancer Res Treat 2016;48:574–582.
Google Scholar | Crossref | Medline34. Benson, R, Madan, R, Kilambi, R, et al. Radiation induced liver disease: a clinical update. J Egypt Natl Cancer Inst 2016;28:7–11.
Google Scholar | Crossref | Medline35. Cheng, JC-H, Wu, J-K, Lee, PC-T, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004;60:1502–1509.
Google Scholar | Crossref | Medline | ISI36. Velec, M, Haddad, CR, Craig, T, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2017;97:939–946.
Google Scholar | Crossref | Medline